Jeffersonville, Indiana Clinical Trials

A listing of Jeffersonville, Indiana clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 42 clinical trials
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.

immunomodulator
endometrial cancer
recurrent endometrial cancer
cancer therapy
olaparib
Research Site
 (5.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +94 other locations
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer ALCHEMIST Chemo-IO Study

This phase III ALCHEMIST trial compares the addition of pembrolizumab to usual chemotherapy versus usual chemotherapy for the treatment of stage IB, II, or IIIA non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the …

squamous cell carcinoma
immunohistochemistry
paclitaxel
cancer
multicentric castleman disease
Jewish Hospital
 (3.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +358 other locations
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. It is the most common form of lung cancer, accounting for around 85% of lung cancers. The purpose of this study is to evaluate the safety and efficacy …

erbb1
anaplastic lymphoma
cancer
stage iv non-small cell lung cancer
measurable disease
University of Louisville /ID# 215195
 (3.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +38 other locations
Tipifarnib for the Treatment of Advanced Solid Tumors Lymphoma or Histiocytic Disorders With HRAS Gene Alterations a Pediatric MATCH Treatment Trial

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have HRAS genetic alterations. Tipifarnib may block the growth of cancer cells that have specific genetic changes in …

refractory peripheral primitive neuroectodermal tumor
cytotoxic chemotherapy
cns involvement
hematopoietic growth factors
refractory hepatoblastoma
Norton Children's Hospital
 (3.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +82 other locations
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The …

eliglustat
imiglucerase
gaucher disease
deficiency
Investigational Site Number 840030
 (3.7 away) Contact site
  • 0 views
  • 04 Dec, 2020
  • +208 other locations
Mucopolysaccharidosis I (MPS I) Registry

The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients …

Investigational Site Number 840030
 (3.7 away) Contact site
  • 0 views
  • 04 Dec, 2020
  • +124 other locations
Pompe Disease Registry

The Pompe Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Pompe disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The objectives …

gaa gene
myozyme
glycogen storage disease type ii
deficiency
replacement therapy
Investigational Site Number 840030
 (3.7 away) Contact site
  • 0 views
  • 22 Dec, 2020
  • +168 other locations
Fabry Disease Registry & Pregnancy Sub-registry

The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The primary …

agalsidase beta
alpha-galactosidase
fabrazyme
fabry's disease
deficiency
Investigational Site Number 840030
 (3.7 away) Contact site
  • 0 views
  • 22 Dec, 2020
  • +125 other locations
Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects

This trial collects research data and samples from patients who experience immunotherapy side effects to store for use in future research studies. Studying research data and samples from patients who experience immunotherapy side effects may help researchers better understand how to predict, prevent, and treat these side effects.

biospecimen collection
Jewish Hospital
 (3.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +380 other locations
A Study of Patients With Chronic Disease

TARGET-RWE is a 10-year, international, longitudinal, observational study of patients with chronic disease designed to specifically address important clinical questions that remain incompletely answered from registration trials. The protocol will follow a master protocol design in which a shared study infrastructure supports progressive development of the registry across the spectrum …

a 10
chronic disease
Family Allergy & Asthma Research Institution
 (8.9 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +3 other locations